text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자 현황\n(기준일: 2018년 12월 31일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투 \xa0자 \xa0자\n서 정 진\n(주)셀트리온\n(주)셀트리온홀딩스\n(주)셀트리온헬스케어\n(주)셀트리온스킨큐어\n(주)셀트리온제약\n티에스이엔씨\n계\n(주)셀트리온\n133-81-23603\n-\n-\n20.06\n-\n2.13\n-\n-\n22.19\xa0\n(주)셀트리온홀딩스\n131-86-24858\n95.51\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n95.51\xa0\n(주)셀트리온헬스케어\n123-81-53473\n35.83\n\xa0-\n\xa0-\n\xa0-\n1.40\n\xa0-\n\xa0-\n37.23\xa0\n(주)셀트리온스킨큐어\n105-86-13560\n69.66\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n69.66\xa0\n셀트리온 유럽\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n-\n-\n셀트리온 돈\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n셀트리온 예브라지아\xa0\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n(주)셀트리온제약\n214-86-71641\n\xa0-\n55.03\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n55.03\xa0\n(주)셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\xa0\n(주)셀트리온화학연구소\n135-81-52064\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n셀트리온팜유에스에이\r\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n티에스이엔엠\n113-81-82345\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n60.00\n60.00\xa0\nCelltrion Global Safety Data Center\n-\n-\n99.99\n-\n-\n-\n-\n-\n99.99\xa0\nCelltrion USA, Inc.\n-\n-\n100.00\n-\n-\n-\n-\n-\n100.00\xa0\n㈜셀트리온 충북대 바이오메딕스\n417-87-01299\n-\n50.00\n-\n-\n-\n-\n-\n50.00\xa0\n㈜셀트리온 충북대 코스메틱스\n338-88-01033\n-\n-\n-\n-\n50.00\n-\n-\n50.00\xa0\n나. 타법인출자 현황\n(기준일 :\xa0\n2018년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc.\n2006.07.14\n신약개발투자\n2,676,548\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n2,277,282\n31,320\n셀트리온 유럽\n2009.07.21\n유럽임상관련투자\n2\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n-\n-\n바이오톡스텍\n2009.07.28\n투자수익\n2,025,000\n1,631,134\n11.24\n11,450,561\n-\n-\n2,104,163\n1,631,134\n11.20\n13,554,724\n57,912,152\n3,601,874\n보스톤 인큐베이션투자조합\n2009.11.27\n투자수익\n2,500,000\n10\n25.00\n143,111\n-\n-\n-\n10\n25.00\n143,111\n1,148,818\n-1,769\n셀트리온 예브라지아\n2009.12.09\n사업다각화\n392\n-\n100.00\n392\n-\n-\n-\n-\n100.00\n392\n-\n-\n셀트리온 돈\n2009.12.09\n사업다각화\n3,239,218\n-\n100.00\n-\n-\n-\n-\n-\n100.00\n-\n1,268,940\n-2,468,967\n제이티비씨\n2017.09.20\n투자수익\n500,000\n100,000\n0.09\n500,000\n-\n-\n-437,006\n100,000\n0.09\n62,994\n179,780,067\n13,296,339\n프리미어 글로벌이노베이션 1호\n2017.06.15\n유망 바이오 벤처기업투자\n250,000\n610\n6.67\n610,000\n1,542\n1,541,700\n-155,693\n2,152\n6.67\n1,996,007\n30,318,519\n-1,531,910\n매일방송\n2011.03.17\n투자수익\n1,000,000\n250,981\n0.45\n1,475,167\n-\n-\n-\n250,981\n0.45\n1,475,167\n435,586,215\n-781,407\n뉴스1\n2011.06.09\n투자수익\n500,000\n60,000\n5.00\n202,251\n-\n-\n-\n60,000\n5.00\n202,251\n17,322,150\n3,576,328\n셀트리온제약\n2013.04.23\n경영참가 등\n50,057,259\n18,377,396\n55.12\n255,342,176\n367,547\n-\n-\n18,744,943\n55.03\n255,342,176\n449,699,183\n-10,237,263\n2014 성장사다리-IMM벤처펀드\n2014.08.11\n투자수익\n2,000,000\n5,113\n20.00\n5,113,400\n-1,120\n-1,120,000\n-816,156\n3,993\n20.00\n3,177,244\n16,215,934\n-3,194,855\n미래에셋셀트리온신성장투자조합 1호\n2017.03.31\n유망 바이오 벤처기업투자\n6,250,000\n125\n50.00\n12,500,000\n125\n12,500,000\n-\n250\n50.00\n25,000,000\n49,168,181\n248,332\nCelltrion Global Safety Data Center\n2018.05.23\n글로벌 의약품 안전성 데이터 관리\n1,106,930\n-\n-\n-\n580,564\n1,204,581\n-\n580,564\n99.99\n1,204,581\n904,786\n-359,494\nCelltrion USA, Inc.\n2018.07.24\n케미컬의약품 판매유통망 구축\n38,973\n-\n-\n-\n1,000\n1,244,660\n-\n1,000\n100\n1,244,660\n1,188,960\n-59,525\n셀트리온충북대바이오메딕스\n2018.07.18\n신약 및 원료의약품 연구개발\n100,000\n-\n-\n-\n20,000\n100,000\n-\n20,000\n50.00\n100,000\n188,580\n-9,956.00\n합 계\n21,413,259\n-\n287,453,409\n969,658\n15,470,941\n695,308\n22,382,917\n-\n303,619,658\n1,242,979,767\n2,109,047\n']"
